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ABSTRACT
The purpose of the present study was to determine the
I

neuronal circuitry responsible for 'K-opioid-mediated

locomotion in preweanling rats.

In two separate

16-day-old rats were given bilateral
I
electrolytic lesions of the ventromedial thalamus and
experiments,

,
I
superior colliculus and, two days later [i.e., postnatal

day (PD)

18]

locomotor activity was assessed after a

systemic injection of the K-opioid[receptor agonist U50,488.
To ensure that lesions to the ventromedial
thalamus or
h
I
superior colliculus did not produce a general disruption of

non-opioid motor systems, the same'rats were retested on PD
i
I
19 and given a systemic injection of- the dopamine receptor
i
agonist R(-)-propylnorapomorphine (NPA).
It was
i
hypothesized that bilateral lesions of the ventromedial
' '
1
thalamus or superior colliculus would attenuate U50,488induced locomotor activity, while liaving no effect on NPAinduced locomotor activity.

i
As predicted,

lesions to the

ventromedial thalamus and superioricolliculus partially

1
blocked U50,488's locomotor activating effects.
i
Importantly, these same lesions failed to disrupt the

locomotor' activity produced by NPAj

iii

A third experiment was

I

conducted to determine whether lesioning unrelated brain
structures would also attenuate U50,488 - induced locomotion.

For Experiment 3, the nucleus accumbens was lesioned

because it was expected that electrolytic lesions of this
brain region would not attenuate U50,488-induced locomotor
activity, while disrupting NPA-induced locomotion.
The
I
results of Experiment 3 were surprising, because: 1)

nucleus accumbens lesions attenuated the locomotor activity
of U50,488-treated rats; and, 2) NPA-induced locomotor

activity was unaffected by nucleus ,accumbens lesions.

It

is not clear why lesions to the nucleus accumbens affected

K-opioid-mediated locomotor activity, but one possibility is

that the nucleus accumbens is a component of the neural
circuitry mediating U50,488-induced locomotion.

Therefore,

when these experiments are considered as a whole, this is
i
the first study to demonstrate that, the nigrothalamic and

nigrotectal pathways mediate, at least partially, the
U50,488-induced locomotor activity of preweanling rats.

I

iv
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CHAPTER ONE

BASAL GANGLIA
4

1

Relevance,
The basal ganglia is a network of interconnected

regions in the brain that form a complex neuronal system

mediating a variety of behaviors,

including motor movement,

cognition, and emotional functioning (Hauber,

1998).

Dysfunctions within the basal ganglia have been linked to a
number of psychiatric and neurological disorders.

For

instance, Parkinson's disease, characterized by difficulty

I
in initiating movements, tremors, and rigidity,

is

associated with degeneration of the nigrostriatal dopamine

pathway (Carlsson, Lindqvist, & Magnusson, 1957; Cotzias,

Papavasiliou, & Gellene, 1969; Fahn,

Nutt, 2000).

1989; Obeso, Olanow, &

Basal ganglia dysfunction has also been

implicated in Huntington's disease

(Haddad & Cummings,

1997), obsessive-compulsive disorder (Miguel, Rauch,

Jenike, 1997), tic disorder (Leckman, Peterson,

Cohen,

1997), dystonia (Cardoso & Jankovic,

dyskenisia

&

Pauls, &

1997), and

(Cardoso & Jankovic, 1997).

Despite the fact that the neurological bases for some
of these disorders are well known (e.g., Parkinson's

1

disease), many disorders resulting 'from basal ganglia

dysfunction are poorly understood. , Determining how the
basal ganglia functions is a first step towards
understanding the etiology of these disorders.

Moreover, a

basic knowledge of basal ganglia anatomy is important for
developing potential pharmacotherapies.

The goal of this

project is to characterize further 'how K-opioid receptors in
!
the basal ganglia modulate motor functioning, particularly
1
during early development.
;

Basal Ganglia Anatomy

Overview
The basal ganglia consists of a set of interconnected

subcortical nuclei

(see Figure 1)

found in the
i

telencephalon, diencephalon, and midbrain (Albin, Young, &
i

Penney,

1989).

The main input structure of the basal

ganglia is the striatum (corresponding to the caudate
I
nucleus and putamen in humans), which receives massive
glutaminergic

(i.e., excitatory)

afferent projections from
!

all over the cortex (Ferino, Thierry, Saffroy,

1987; Parent,

1990; Wilson,

& Glowinski,

1987)., The striatum,

in turn,

sends projections to the substantia nigra, the main output
nuclei of the basal ganglia, via a direct

2

(striatonigral)

I

I
I

pathway and an indirect

(striatopaljlidal) pathway (Gerfen,

1992b; Smith, Bevan, Shink, & Bolam, 1998).
The substantia
I
nigra then sends its own output projections to the
i
I
thalamus, superior colliculus, and pedunculopontine nucleus
1992a; Gerfen, Staines, Arjbuthnott, & Fibiger,
,
i
1982; Parent & Hazrati, 1995).
1
i
The three target projections of the substantia nigra
(Gerfen,

'
I
pars reticulata (i.e., the thalamusi, superior colliculus,
send iexcitatory (i.e.,
i
glutaminergic) projections to varidus brain regions.
i

and pedunculopontine nucleus)

First,

the thalamus sends an excitatory projection back to

I
the cortex and striatum (Mengual, de las Heras, Erro,

Lanciego, & Gimenez-Amaya,

iSecond, the superior
■ i
colliculus transmits an excitatory 'projection to the

1999) .

thalamus and cortex (Benevento & Fallon,

Harting, Huerta, Frankfurter, Strominger,

1975; Binns,

1999;

& Royce, 1980).

Third, the pedunculopontine nucleus sends a feedback

projection to the substantia nigra pars compacts (Charara,
I
Smith,

& Parent, 1996) and the subthalamic nucleus

Bolam,

1995; Lavoie & Parent, 1994)( .

Therefore,

(Bevan &

it should be clear,why the organization of

the basal ganglia has been described in terms of parallel

loopings,

in which distinct circuitries are formed between

3

Glutamate

PEDUNCULOPONTIN
E NUCLEUS

Glutamate

SUBSTANTIA NIGRA
PARS RETICULATA

Figure 1.
Major efferent and afferent pathways of the
basal ganglia. The striatum receives input from all over
the cortex and sends projections to the substantia nigra,
via a direct pathway and an indirect pathway.

4

the cortex, striatum, substantia nigra, and thalamic output

systems

(Alexander & Crutcher,

Strick,

1986).

199Q; Alexander, DeLong, &

Specifically, discrete cortical information

is cycled through regions of the basal ganglia and sent

back, via the thalamus, to discrete cortical areas, thereby
I
forming a circular loop between the cortex and the basal

Five such parallel circuitries have been

ganglia.

identified: 1) motor; 2)

prefrontal; 4)

cingulate
1986).

oculomotor; 3) dorsolateral

I
lateral orbitofrontal; and 5) anterior

1990; Alexander et al.,
I
Different functional roles.are thought to be
I

(Alexander & Crutcher,

associated with each of these circhitries, and they
I
collectively comprise the diversity of behaviors associated

with the basal ganglia.

,
i
In summary, the basal ganglia'is a complex network of

interconnected brain regions that receives massive input
from all over the cortex.

The major input structure is the

striatum, which transmits cortical, information via a direct

and indirect pathway down to the substantia nigra pars
reticulata, the main output structure of the basal ganglia.

Information is then relayed through the thalamus to several
regions of the cortex, thereby completing the cortical
loop.
5

Striatonigral and Striatopallidal Pathways
Excitatory input from the cortex is transmitted to the

substantia nigra pars reticulata through a direct
(striatonigral) pathway and an indirect

(striatopallidal)

pathway (Albin et al., 1989; Gerfen, 1992b).

In the direct

pathway, corticostriatal input is transmitted directly to
the substantia nigra pars reticulata

(see Figure 1).

Neurons which provide this input are GABAergic, but also
release two neuropeptides: dynorphin and substance P

(Gerfen & Young,

Gerfen,

1988; Smith et al,

1998; Steiner &

1998) .

i
In contrast, the indirect pathway sends cortical
I
information to the substantia nigra pars reticulata via an

array of interconnections involving the globus pallidus and

subthalamic nucleus (see Figure 1)

(Smith et al.,

1998).

I
GABAergic neurons originating in the striatum, which

express and release enkephalin and•substance P
Young,

(Gerfen &

1988; Steiner & Gerfen, 1998), first provide

corticostriatal input to the globus pallidus.

The globus

pallidus then sends an inhibitory projection to the
subthalamic nucleus.

Two output pathways leave the

subthalamic nucleus: an excitatory feedback circuit to the

6

globus pallidus and an excitatory connection to the

substantia nigra pars reticulata.

[

Different dopamine receptors are associated with the

two striatal projections to the substantia nigra pars
I
reticulata (i.e., the direct and indirect pathways).

Striatonigral GABAergic neurons generally express dopamine
DI receptors, whereas striatopallidal GABAergic neurons

express dopamine D2 receptors

(Gerfen,

1992b; Gerfen,

Engber, Mahan, Susel, Chase, Monsma, & Sibley,

Steiner & Gerfen,

1998).

1990;

Only a small number of

striatonigral and striatopallidal neurons express both
dopamine receptor subtypes

(Steiner & Gerfen,

1998) .

Nigrotectal and Nigrothalamic Pathways
i
The opioid rich substantia nigra pars reticulata
I
serves as the main output structure for the basal ganglia.

There are three prominent output pathways exiting the

substantia nigra pars reticulata, and they project to the

superior colliculus (nigrotectal pathway), thalamus
(nigrothalamic pathway), and pedunculopontine nucleus
(nigropedunculopontine pathway)(see Figure 1)

Chevalier,

(Deniau &

1992; Gerfen, 1992b; Steiner & Gerfen,

1998).

Each of these output pathways are inhibitory, because the
i
neurons comprising these connections release GABA.
In

7

fact, the classic view of basal ganglia functioning is that
these target regions are under tonic inhibition from the

substantia nigra pars reticulata arid that the loss of this
tonic inhibition results in basal ganglia-mediated behavior
(Albin et al.,

1989; Chevalier & Deniau,

1990) .

For

instance, unilateral microinjectioris of GABA into the

substantia nigra pars reticulata produces contralateral

circling, presumably by inhibiting .the inhibitory output
pathways of the substantia nigra pars reticulata, resulting
t
in a disinhibition of the superior 'colliculus and
ventromedial thalamus

(Kaakkola & Kaariainen,

Kameyama, Okuyama, Hashimoto,

& Aihara,

1980; Kamata,

1985).

Nigrostriatal Pathway

One of the major ascending dopaminergic projections in
the brain originates in the substantia nigra pars compacta

and terminates in the striatum (Cooper, Bloom, & Roth,
2003; Joel & Weiner, 2000).

Interestingly, dopaminergic

input via the nigrostriatal tract differentially affects
the direct and indirect efferent pathways of the striatum

Specifically, dopaminergic input excites

(see Figure 1).

the striatonigral

striatopallidal
Crutcher,

(i.e., direct) pathway,

(i.e.,

and inhibits the

indirect) pathway (Alexander &

1990; Gerfen & Young, 1988).
8

Thus, the role of

I

dopamine within the striatum may be' to strengthen cortical
input to the striatum by inhibiting the direct pathway and

facilitating the indirect pathway (Alexander & Crutcher,
1990) .

The K-opioid receptor system modulates the activity of

dopamine neurons comprising the nigrostriatal pathway.

For

example, K-opioid receptor stimulation in the substantia

nigra pars compacta decreases the firing rates of dopamine
neurons, thus attenuating dopamine 'release in the striatum
I ■
(Walker, Thompson, Frascella, & Friederich,

1987) .

Similarly, at the terminal region of the nigrostriatal
pathway (i.e., the striatum), stimulation of presynaptic
opioid receptors inhibits the release of dopamine

k-

(Di

1988; Werling, Frattali, Portoghese,
1
& Cox, 1988; Zaratin & Clarke, 1994) .
In

Chiara & Imperato,

Takemori,

summary, dopaminergic activity within the nigrostriatal

pathway partially mediates motor functioning, and it is
clear that K-opioid receptors have a significant role in

modulating this effect.
Mesocortical and Mesolimbic Pathways

The second of the major ascending dopaminergic
pathways briginates in the ventraltegmental area (Oades &

9

Halliday,

These cell bodies' send prominent

1987) .

projections to cortical and limbic .regions
2003).

(Cooper et al.,

I
The mesocortical pathway is comprised of dopamine

fibers projecting to various cortical structures, including
the medial prefrontal cortex, cingulate cortex, and

entorhinal areas.

In contrast, projections to various

limbic structures, such as the most ventral part of the

striatum (i.e., nucleus accumbens) and amygdala, constitute
I
the mesolimbic pathway.

]

I
Dopaminergic activity within the mesolimbic pathway is
affected by |i- and K-opioid receptor activity (see Figure
I

For instance, stimulating p.-opioid receptors in the
I
ventral tegmental area has the effect of inhibiting
2) .

GABAergic neurons that tonically inhibit dopamine
projections to the striatum (Di Chiara & Imperato,
i
Spanagel, Herz,

& Shippenberg,

1990; 1992).

1988;

In other

words, jx-opioid agonists disinhibit neurons of the

mesolimbic pathway by inhibiting GABAergic activity within
the ventral tegmental area.

I
In contrast, K-opioid receptor

stimulation inhibits dopaminergic activity.

Specifically,

K-opioid receptor agonists decrease dopaminergic functioning
I
in the nucleus accumbens by directly inhibiting dopamine

10

Figure 2.
Dopaminergic activity of the mesolimbic pathway
is modulated by pi- and K-opioid receptor stimulation.
Increased |i-opioid activity increases dopamine release in
the nucleus accumbens by inhibiting GABAergic activity,
whereas increased K-opioid stimulation decreases dopamine
release in the nucleus accumbens.

release at the terminal button (Spanagel et al.,
1992) .

1990;

When considered together, it is clear that //- and K

opioid receptor activity has opposing actions on the
mesolimbic pathway, with //-opioid receptor stimulation

11

indirectly enhancing neurotransmission, while K-opioid

receptor stimulation inhibits dopamine release within the

nucleus accumbens.

12

CHAPTER TWO

K-OPIOID RECEPTOR,SYSTEMS

Overview
I

K-Opioid receptor systems are involved in regulating
Dynorphin

motor control within the basal ganglia.
peptides,

the endogenous ligands that primarily bind to

opioid receptors

(Chavkin, James, & Goldstein,

Corbett, Paterson, McKnight, Magnan,

k-

1982;

& Kosterlitz, 1982),

are present in high concentrations'in the substantia nigra
I

pars reticulata (Zamir, Palkovits,& Brownstein, 1983;
!•
1984).
Dynorphin peptides are synthesized in cell bodies

located in the striatum and are ultimately released from
w■

f

terminal fibers in the substantia nigra.

These peptides

serve as neuromodulators, because dynorphin, applied
locally into the substantia nigra pars reticulata,

modulates the activity of GABAergic cells projecting to the
I

ventromedial thalamus and superior' colliculus

Garcia-Munoz,

1985; Robertson, Hommer,

(Lavin &

& Skirboll,

1987).

Dynorphin-induced modulation of these GABAergic output
pathways produces robust contralateral circling in adult
rats

(Friederich, Friederich, & Walker,
i

Lohof, Patrick,

& Walker,

1987; Matsumoto,

1988b; Morelli & Di Chiara,

13

1985).

Hence, it is clear that K-opioid receptor systems

have an important role in regulating motor control.

K-Opioid Receptor Classification
Over the last two decades the presence and specificity
of K-opioid receptors have been determined.

Specifically,

the existence of three K-opioid receptors have been

established: Kl,
Gacel, Huang,

and, more recently,

k2,

& Pasternak,

(Cheng, Roques,

k3

1992; Clark, Liu,

Price, Hersh,

1989; Fowler & Fraser,
i

Edelson, & Pasternak,

1994; Leslie &

Loughlin,; 1994; Mansour, Burke, Pavlic, Akil,

1996; Mansour, Fox, Akil, & Watson,

1995).

& Watson,

The Kl-opioid

receptor subtype has a high affinity for the endogenous
I
peptide dynorphin A and exogenous arylacetamide drugs such

(Leslie & Loughlin,

as U50,488 and U69,593

1994; Unterwald,

Knapp, & Zukin,

1991).

opioid peptides

(e.g., P-endorphin), as well as for

The K2-opioid receptor has
I
considerable affinity for dynorphin A and other endogenous

exogenous compounds such as diprenorphine,
ethylketo'cyclazocine, and bremazocine
1994).

Because the

(Leslie & Loughlin,

-opioid receptor was discovered

k3

recently, less is known about the affinity of endogenous
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peptides for this receptor subtype.

However, the exogenous

compound naloxone benzoylhydrazone has been Identified as

having a high affinity for

-opioid receptors

(Cheng et

k3

al., 1992; Clark et al., 1989).

K-Opioid Receptor Distribution

Adult Brain
Localization of Kl- and K2-opipid receptors in the
adult rat brain has been well established, with

-opioid

k2

receptors being more abundant than Kl-opioid receptors

(Unterwald et al.,
& Tempel, 1988) .

1991; Zukin, Eghbali, Olive, Unterwald,

Kl-opioid receptors are found in the

caudate-putamen (i.e.,

striatum), nucleus accumbens, medial

I
nucleus of the thalamus, superior colliculus,

substantia

nigra pars reticulata, ventral tegmental area, and

hypothalamus
1991).

(Mansour et al. ,

1996;: Unterwald et al. ,
I

-opioid receptors are found throughout the brain,

k2

including several regions of the thalamus,

inferior

colliculus, amygdala, olfactory tubercles, endopiriform

nucleus, claustrum, substantia nigra, nucleus accumbens,
and striatum (Unterwald et al.,

1991; Zukin et al.,

1988).

Relatively few studies have examined the distribution of
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k3-

opioid receptors, although binding sites for this receptor

have been recognized in the hypothalamus, thalamus,
striatum, and midbrain (Cheng et al.,

Ontogeny

1992) .

j

The ontogenesis of K-opioid repeptors has been
I

examined, although the development of individual K-opioid
receptor subtypes has received minimal empirical study (but

1989; Kitchen,

see Allerton, Smith, Hunter, Hill, & Hughes,

Kelly, & Viveros,

1990) .

K-Opioid receptors begin to emerge

in rat brain as early as embryonic day (ED)

14.5 and

continue to increase in density unt il ED 18.5, where they

remain stable until birth (Leslie

Loughlin,

1994).

After

birth, the developmental pattern of K-opioid receptors is

more controversial.

For example, one study has reported

that adult-like K-opioid receptor concentrations are
attained sometime between postnatal day (PD)

(Petrillo, Tavani, Verotta, Robson,

7 and PD 14

& Kosterlitz,

1987).

In contrast, Spain and colleagues report a more complex

pattern of development, as they found that K-opioid receptor

densities simultaneously increase in hindbrain and decrease
in forebrain across the first postnatal week (Spain, Roth,

& Coscia,

1985).

This effect .is reversed during the second
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postnatal week, with forebrain K-opioid receptor densities

increasing and hindbrain K-opioid peceptor densities

decreasing.

Reductions in hindbrain receptor densities are

attributed to a lack of K-opioid receptor binding sites in
I

the cerebellum, a structure which undergoes substantial

growth during this time

(Spain et al.,
I

1985).

Age-dependent changes in K-opioid receptor densities
have not been ascribed to specific brain regions, because
I
ontogenetic studies have primarily'focused on K-opioid

receptor binding in whole brain or jspinal cord (see
Allerton et al., 1989; Attali, Saya, & Vogel, 1990;

Petrillo et al., 1987; Spain et al.,

1985).

Nevertheless,

receptor autoradiography has revealed that by PD 20 K-opioid
receptors are present in the striatum, nucleus accumbens,

olfactory tubercle, hypothalamus, amygdala, and thalamic

regions

(Kornblum, Hurlbut, & Leslie,
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1987) .

CHAPTER THREE
BEHAVIORAL EFFECTS OF K-OPIOID

RECEPTOR STIMULATION
i

Adult Studies
i

Behavioral effects of K-opioid receptor stimulation in
adult rats have been well characterized.

Systemic

injections with various K-opioid receptor agonists

(e.g.,

decrease the locomotor

U50,488, PD 117302, and enadoline)

activity, rearing, and grooming of adult rats and mice

(Castellano & Pavone, 1987; Jackson & Cooper,

Leighton, Johnson, Meecham, Hill, & Hughes,
Stewart,

1992; Ukai & Kameyama, 1985).
I
I

1988;

1987; Leyton &

Decreased

behavioral activity can be reversed by the highly selectivei
i

K-opioid receptor antagonist nor-binaltorphimine

(nor-BNI)

(Portoghese, Lipkowski, & Takemori,1 1987; Takemori, Ho,
Naeseth, & Portoghese, 1988), indicating that K-opioid
I

receptors mediate this behavioral effect

Terenius, & Ogren, 2000).

(Kuzmin, Sandin,

The actions of K-opioid.receptor

agonists are dose-dependent, because lower doses

(0.1-1.0

mg/kg) of U50,488 have no effect on behavioral activity,

while higher doses

(5.0-10.0 mg/kg)
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significantly reduce

locomotion, rearing, and grooming (Leighton et al.,
Leyton & Stewart, 1992; Ukai & Kameyama,

1987;

1985).

Two exceptions to this pattern: of results have been
reported.1 First, Kuzmin and colleagues demonstrated that

non-habitiiated mice (i.e., mice that had not been
acclimated to the testing chamber) 'exhibited enhanced
locomotion 40 min after being given a low dose

mg/kg) of U50,488

(Kuzmin et al. , 2000).

(1.25 or 2.5

In contrast, mice

I
allowed to explore the testing chamber 30 min before
I
receiving an injection of U50,488, .failed to exhibit the
I
same enhanced locomotor response, 'importantly, systemic
I
injections of nor-BNI failed to block the increased

locomotor activity exhibited by non-habituated mice,

indicating that this was not a K-opioid-mediated effect

(Kuzmin et al., 2000).
I
Second, systemic injections of K-opioid receptor
agonists have different behavioral actions depending on the

species being studied.

Specifically,

adult hamsters show

enhanced locomotor activity after a systemic injection of a

low dose of U50,488

(1.0 mg/kg)

(Schnur & Walker,

systemic injection of a high dose

(10 mg/kg)

1990).

of U50,488,

however, decreased the locomotor activity of hamsters.
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A

Thus, both adult hamsters and adult' rats show decreased

locomotor activity after systemic administration of a Kopioid receptor agonist.

'

It is unlikely that the U50,488-induced locomotor
1.
activity of adult hamsters was a result of a non-opioid
1
effect, because the increased locomotion was attenuated by

a systemic injection of naloxone
receptor antagonist).

(a non-specific opioid

Rather, Schnur and Walker (1990)

suggest that regional differences in the densities of

k-

opioid receptors may account for tbe different behavioral

patterns exhibited by U50,488-treated rats and hamsters.
More precisely, adult hamsters have comparatively greater

densities of K-opioid receptors in'the substantia nigra pars
reticulata than adult rats.

Importantly, adult rats show

i
increased locomotor activity when the substantia nigra pars
reticulata is stimulated by microinjections of K-opioid
receptor agonists

al.,

1988b).

(Friederich et al., 1987; Matsumoto et

Thus,

it is probable that low doses of

U50,488 increase the locomotor activity of adult hamsters

by preferentially stimulating K-opioid receptors in the

substantia nigra pars reticulata. 1

I
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In sum,

systemic administration of K-opioid receptor

agonists to adult rats and mice typically results in

reduced behavioral activity.

Interestingly, systemically

administering a low dose of a K-opioid receptor agonist
enhances the locomotor activity of'adult hamsters.

The

latter effect is probably caused by preferential

stimulation of K-opioid receptors in the substantia nigra

pars reticulata, because adult hamsters have a greater

abundance of K-opioid receptors in this area compared to
adult rats

(Schnur & Walker,

1990) ■.

The ability of K-opioid receptor agonists to suppress

the locomotor activity of adult rats is probably due to

decreased dopaminergic neurotransmission.

Specifically,

when U50,488 is given systemically1, decreased dopamine

release is evident in the nucleus accumbens and striatum

(Di Chiara & Imperato, 1988; Maisonneuve, Archer,
1994; Zaratin & Clarke,

1994).

& Glick,

This decrease in

dopaminergic activity may be responsible for U50,488's
Consistent with this

locomotor inhibiting effects.

hypothesis, increased dopamine neurotransmission within the
I
nucleus accumbens and striatum, caused by microinjecting
I
dopamine agonists into these brain regions, enhances the
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locomotor activity of adult rats

(Essman, McGonigle, &

Lucki, 1993; Kelley, Lang, & Gauthier, 1988).
The means by which K-opioid receptor agonists modulate

dopaminergic neurotransmission are .well known, as systemic

administration of a K-opioid receptor agonist decreases

dopamine activity via two independent mechanisms.

One

mechanism involves stimulation of presynaptic K-opioid
receptors located on dopamine terminals in the nucleus

accumbens and striatum.

Local application of U50,488 into

these regions directly inhibits the release of dopamine

(see Figure 2), an effect that can be blocked by K-opioid

receptor antagonists

(Werling et al., 1988).

A second mechanism involves decreasing the neuronal
activity of the nigrostriatal pathway.

Specifically, the

firing rates of dopaminergic nigrostriatal cells are

inhibited when U50,488 is either administered systemically

or microinjected into the substantia nigra pars reticulata.
This reduction in neuronal firing rates causes decreased
dopamine release in the striatum (Thompson & Walker,

1990;

Walker et al., 1987; but see Lavin' & Garcia-Munoz, 1985).
Regardless of the mechanism (i.e.f| stimulating presynaptic

K-opioid receptors or reducing neuronal firing rates),
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k-

opioid receptor agonists reduce the locomotion of adult
rats by decreasing dopamine transmission in the striatum

and/or nucleus accumbens.
In contrast to systemic administration, microinjecting

K-opioid receptor agonists into the substantia nigra pars
reticulata of adult rats produces a dramatically different

behavioral effect.

Specifically, unilateral infusion of

U50,488 into the substantia nigra pars reticulata results
in robust contralateral circling (lyiatsumoto, Brinsfield,

Patrick, & Walker, 1988a; Thompson & Walker,

1992) .

Similar effects are observed when various dynorphin
peptides

(i.e., endogenous ligandsJfor K-opioid receptors)

are administered into the substantia nigra pars reticulata.
' I
For instance, unilateral microinjections of dynorphin A(1_8),
dynorphin A(i_i7), or dynorphin B into the substantia nigra

pars reticulata of adult rats, produces robust

contralateral circling (Friederich;et al.,
Marschitz', Christensson-Nylander, Sharp,

Hokfelt, Terenius, & Ungerstedt,

1987; Herrera-

Staines, Reid,

1986; Herrera-Marschitz,

Hokfelt, Ungerstedt, & Terenius, 1983; Herrera-Marschitz,
Hokfelt, Ungerstedt, Terenius, & Goldstein,

1984; Matsumoto

et al.,

The finding

1988b; Morelli & Di Chiara,
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1985).

that route of administration (i.e., systemic vs.
intracranial) produces dramatically different behavioral

effects in adult rats, suggests that K-opioid receptor

stimulation has two distinct actions: an inhibitory and a
stimulatory effect on locomotor activity.

One possibility is that the locomotor stimulating

I
effects of K-opioid receptor agonists are caused by

increased dopamine neurotransmission in the nigrostriatal

and/or mesolimbic pathways.

This explanation seems

unlikely for three reasons.

First,( K-opioid receptor

stimulation decreases, rather than 1 increases, dopaminergic
I

neurotransmission by diminishing the firing rate of

substantia nigra pars compacta dopamine neurons projecting
to the striatum (Walker et al.,

I
1987).

Second, lesions of

the nigrostriatal pathway fail to inhibit the contralateral
I
circling produced by microinjecting U50,488 into the

substantia nigra pars reticulata (1986; Herrera-Marschitz
et al.,

T984; Morelli & Di Chiara,

1985).

Third, lesions

I
of the striatum potentiate, rather.than attenuate, K-opioid

induced circling (1986; Herrera-Marschitz et al.,

1984).

When considered together, it appears that K-opioid-induced

locomotor activity is not mediated by dopaminergic systems.
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Rather, there is evidence suggesting that the enhanced
motor movement induced by K-opioid receptor stimulation of

the substantia nigra pars reticulata is a result of
disinhibiting GABAergic output neurons originating in the

substantia nigra pars reticulata and projecting to the
ventromedial thalamus and superior colliculus
Walker,

1992).

(Thompson &

More precisely, under normal conditions the

substantia nigra tonically inhibits the motor circuits of
the superior colliculus and the ventromedial thalamus via

GABAergic output fibers

(see Figure 3A).

K-Opioid receptor

stimulation in the substantia nigra pars reticulata

inhibits these GABAergic output neurons and keeps them from

inhibiting the ventromedial thalamus and superior
colliculus

(see Figure 3B).

Thus, through the process of

disinhibition, K-opioid receptor agonists administered into
the substantia nigra pars reticulata cause increased motor

movement by removing the superior colliculus and
ventromedial thalamus from inhibition.

When considered together, it is evident that K-opioid
receptor stimulation has two different, but concurrent,

actions in the adult rat.

First, K-opioid receptor agonists

inhibit locomotor activity by decreasing dopamine release
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PREMOTOR AREAS

STRIATUM

Figure 3. Representation of the normal activity of
substantia nigra pars reticulata neurons.
During normal
conditions, the substantia nigra pars reticulata inhibits
the thalamus and superior colliculus (Upper diagram).
Dynorphin stimulates K-opioid receptors located on the
GABAergic output projections of the substantia nigra pars
reticulata.
The dynorphin inhibits these GABA neurons,
thus disinhibiting neurons in the ventromedial thalamus
and superior colliculus (lower diagram).
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Second, K-opioid

in the nucleus accumbens and striatum.

receptor agonists stimulate locomotor activity by
disinhibiting the GABAergic output neurons of the

nigrothalamic and nigrotectal pathways.

Apparently, the

locomotor inhibiting effects of K-opioid receptor agonists
(mediated by the dopaminergic nigrostriatal and/or
i

mesolimbic pathways), overwhelm the locomotor activating

effects of K-opioid receptor agonists

(mediated by GABAergic

nigrotectal and nigrothalamic pathways).

This conclusion

is based on the finding that systemic administration of
U50,488 decreases the locomotor activity of adult rats.

Ontogenetic Studies
K-Opioid receptor stimulation.produces a dramatically

different effect in preweanling rats when compared to

Specifically, increased locomotor activity is

adults.

evident after systemic injections of U50,488 or enadoline
in 3-,

5-,

Clair, & McDougall,

Crawford,

(Bolanos, Garmsen,

10-, or 17-day-old rats

1996; Collins, Zavala,

& McDougall,

Ingersoll, Duke,

1998; Duke, Meier, Bolanos,

Crawford, & McDougall, 1997; Jackson & Kitchen,

McDougall, Rodarte-Freeman, & Nazarian,

1989;

1999; McLaughlin,

J

Tao, & Abood,

1995).

The longevity of this effect is
27

restricted to the preweanling period, however, because 35day-old rats, like adult rats, do not exhibit enhanced
motor movement after a systemic injection of U50,488
(Bolanos et al.,

1996).

I
U50,488's and enadoline's actions

are mediated by K-opioid receptors, since systemic
injections of nor-BNI block U50,488- and enadoline-induced

locomotor activity in 3- and 18-day-old rats (Collins,
I
Zavala, Nazarian, & McDougall, 2000; McLaughlin et al.,
1995).

At present, it is not known why systemic
administration of a K-opioid receptor agonist enhances the

locomotor activity of preweanling rats.

One possibility is

that K-opioid receptor agonists activate the nigrostriatal

or mesolimbic dopamine pathways.

This seems unlikely,

however, because decreasing dopamine transmission with

methyl-DL-p-tyrosine

(AMPT)

d'-

fails to attenuate U50,488-

induced locomotor activity of preweanling rats
Garmsen, Meier, & Crawford, 1997).

(McDougall,

Importantly, depleting

dopamine with AMPT is effective at' reversing the locomotor
activity induced by amphetamine (an indirect dopamine

agonist).

Therefore, it appears that the K-opioid-induced

28

locomotor activity of preweanling rats is not mediated

through dopaminergic mechanisms.

A second possibility is that K-opioid receptors in the
substantia nigra pars reticulata mediate the locomotor
This explanation has

activating effects of U50,488.

received empirical support, because microinjecting UFO,488
into the substantia nigra pars reticulata causes a dosedependent increase in the locomotor activity of 18-day-old
rats

(Collins et al., 2000).

Importantly, this U50,488-

I
induced locomotor activity was blocked by both systemic and
intra-nigral injections of nor-BNI-, but not by infusions of

nor-BNI into the dorsal striatum (Collins et al., 2000).

When considered together, it is clear that young rats
exhibit robust motor responses after systemic or intranigral injections of a K-opioid receptor agonist.

It is

also clear that K-opioid receptors' within the substantia

nigra pars reticulata mediate this psychopharmacological
effect.

i
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CHAPTER FOUR

SUMMARY AND HYPOTHESES

Summary and Purpose

Stimulation of K-opioid receptors by systemic
I
injections of U50,488 decreases the locomotor activity of
adult rats.

This effect is probably caused by decreased

dopaminergic neurotransmission in the nucleus accumbens and
striatum.

In contrast, stimulation of K-opioid receptors in

the substantia nigra pars reticulata produces enhanced
I
motor movement in adult rats.
For instance, unilateral
I
microinjections of U50,488 or dynorphin peptides

(e.g.,

dynorphin A(i_8), dynorphin A(i_i7), o,r dynorphin B) into the
i
substantia nigra pars reticulata causes contralateral

circling

(Friederich et al. ,

1983; 1984; Matsumoto et al.,

1987;' Herrera-Marschitz et al. ,

1988a; Morelli & Di Chiara,

K-Opioid-induced circling in adult rats is a result
i
of disinhibiting the nigrotectal and nigrothalamic premotor
1985).

pathways

(Thompson & Walker,

1992),.

In summary, K-opioid

receptor agonists differentially affect the locomotor
I

activity of adult rats, depending on what brain areas are
affected: Systemic injections of U50,488 decrease locomotor

activity in adult rats, while microinjecting U50,488 into
30

I

the substantia nigra pars reticulata enhances motoric

movement.
Unlike in the adult rat,

systemic administration of a

K-opioid receptor agonist increases the locomotor activity
of preweanling rats.

For instance,

systemic injections of

U50,488 enhances the motor responses of 3-,

day-old rats

(Bolanos et al.,

Duke et al.,

1997; Jackson & Kitchen,

al.,

1999; McLaughlin et al.,

5-,

10-, or 17-

1996; Collins et al.,

1995).

1998;

1989; McDougall et

The substantia nigra

pars reticulata is the neuroanatomical locus for this

k-

opioid-mediated effect, since intranigral injections of

U50,488 cause a dose-dependent increase in locomotor
activity (Collins et al., 2000) .

Until now, however, no
I

study has determined which nigral output pathway mediates
U50,488-induced locomotor activity,in preweanling rats.

It is possible that U50,488 enhances the locomotor
activity of preweanling rats by disinhibiting GABAergic

projections from the substantia nigra pars reticulata to
i
the ventromedial thalamus and superior colliculus.

The

only support for this hypothesis comes from a nonontogenetic study which showed that the U50,488-induced

contralateral circling of adult rats is attenuated by
i
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I

lesions to the ventromedial thalamus and superior
colliculus (Thompson & Walker, 1992). . If a similar
mechanism mediates the K-opioid-induced locomotor activity
I
of preweanling rats, then lesions to the ventromedial
thalamus and superior colliculus should disrupt U50,488's

locomotor activating effect.

Alternatively, if other

nigral output pathways are responsible for K-opioid-mediated
motor movement, then lesions to the ventromedial thalamus

and superior colliculus should be ineffective at reducing
U50,488-induced locomotor activity!

The purpose of this thesis, therefore, was to
I
determine the neuronal circuitry mediating U50,488-induced
locomotion in preweanling rats.

To this end, preweanling

rats received bilateral electrolytic lesions of the

ventromedial thalamus or superior colliculus and, two days
later, the same rats received a challenge injection of

U50,488.

It was predicted that bilateral lesions of the

ventromedial thalamus or superior colliculus would

attenuate the U50,488-induced locomotor activity of 18-dayold rats.
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'
Experimental Controls
j
I
When! interpreting the effects(of brain lesions on

drug-induced changes in locomotor activity it is important
i
1
'
• ’
to determine whether the lesion caused a generalized

disruption of normal motoric functioning.

If motor ability

was compromised, interpretation of I drug-induced behavioral
'
I
changes would be problematic.
,

Thus, in the present study
i
.

two measures were taken to ensure trhat lesions to the
i
1
' :
I
ventromedial thalamus and superior|colliculus did not
I
produce a general deficit in motorifunctioning.
I
First, baseline levels of locomotor activity were
assessed prior to U50,488 injections to determine whether
J
i
- ;
the lesions caused a change in.basal activity.
Second, to
ensure that the functioning of non-opioid motor systems

!
.
i
were not affected by lesions of the nigrothalamic and
I
i
i
. *;
nigrotectal pathways, drug-induced changes in locomotor
;
' I
activity were assessed after a systemic injection of the

dopamine agonist R(-)-propylnorapomorphine (NPA).
When
,
i •
given sys'temically, NPA increases the locomotor activity of
.
'
'
i
rats via dopaminergic mechanisms (Duke et al., 1997;
i
!
:
i
Kafetzopoplos, 1986; Kelly & Roberts, 1983) .
Thus, NPA!:
.
1
induced increases in locomotor activity were expected to be
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largely unaffected by lesions of the ventromedial thalamus

and superior colliculus.

For this study, it was also important to determine the
specificity of brain lesions.

In other words, it was

necessary to provide an anatomical control to determine
whether lesioning unrelated brain structures also reduces

U50,488-induced locomotion.

Consequently, an additional

experiment was conducted where separate groups of rats were
given bilateral electrolytic lesions of the nucleus
accumbens and tested with U50,488.

The nucleus accumbens •

is not thought to mediate U50,488-induced locomotor

activity, so lesioning this structure was not expected to
impact U50,488's behavioral effects.

Thus,

it was

predicted that bilateral lesions of the nucleus accumbens
would fail to attenuate the U50,488-induced locomotor
activity of 18-day-old rats.

Conversely, lesions to the

nucleus accumbens were expected to disrupt NPA-induced

locomotor activity,

since NPA's actions are known.to be

mediated by the mesolimbic pathway (Kafetzopoulos,
Kelly & Roberts,

1983).
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1986;

Hypotheses
In summary, three separate experiments were conducted.

In the first experiment, rats received bilateral lesions of

the ventromedial thalamus and locomotor activity was
assessed after systemic injections of U50,488 or NPA.

It

was hypothesized that: 1) lesions of the ventromedial
thalamus would attenuate U50,488-induced locomotor

activity; and 2)

lesions of the ventromedial thalamus would

fail to affect NPA-induced locomotion.

In the second

experiment, rats received bilateral lesions of the superior

colliculus and locomotor activity Was assessed after
systemic injections of U50,488 or NPA.

that: 1)

It was hypothesized

lesions of the superior colliculus would attenuate

U50,488-induced locomotor activity; and 2)

lesions of the

superior colliculus would have no effect on NPA-induced
locomotion.

In the third experiment, rats received

bilateral lesions of the nucleus accumbens and locomotor
activity was assessed after systemic injections of U50,488

or NPA.

It was hypothesized that:11)

lesions of the

nucleus accumbens would fail to attenuate U50,488-induced
locomotor activity; and 2)

lesions!of the nucleus accumbens

would disrupt NPA-induced locomotion.
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CHAPTER FIVE
GENERAL METHODS

Subj ects i

Subjects were 84 male and female rats of SpragueDawley descent

(Harlan) born and raised at California State

University, San Bernardino.
pups by PD 3.
surgery.

Litters were culled to 10 rat

Pups remained with the dam until time of

At PD 16, rats were randomly assigned to groups.

No more than one rat from each litter was placed into a

particular group.

Effort was made to ensure an equal

number of male and female rats in each group.

The colony

room was maintained at 22°C-24°C and kept on a 24 h
I
light/dark cycle (lights on at 6:00 am).

Apparatus
Behavioral testing was done in commercially available
(Coulbourn Instruments, Allentown, PA)
chambers

activity monitoring

(25.5 x 25.5 x 41 cm), consisting of Plexiglas

walls, a plastic removable floor, and an open top.

Each

chamber included an X—Y photobeam array, with 16 photocells
and detectors, which were used to determine distance

traveled (a measure of horizontal locomotor activity).
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Drugs

(±)- trans-U50,488 methanesulfonate,(U50,488)

and R(-)-

propylnorapomorphine hydrochloride1 (NPA) were obtained from
Sigma

(St. Louis, MO) and dissolved in distilled water.

Both U50,488 and NPA were injected, intraperitoneally (ip)
at a volume of 5 ml/kg.

Surgery
On PD 16, rats were anesthetized with a solution of

ketamine and xylazine (Sigma) and placed on a Cunningham
Neonatal Rat Adapter attached to a1 standard Kopf

stereotaxic apparatus

(Cunningham & McKay, 1993) .

A single

incision was made mid-sagitally al.ong the skull and the

skin was retracted.

Separate groups of rats were then

given bilateral electrolytic lesions of the ventromedial
!
thalamus

(Experiment 1), superior colliculus
I

2), or nucleus accumbens

(Experiment

(Experiment 3).

I
Electrolytic lesions were made by passing anodal
I
constant current (1.0 mA, Grass DC Lesion Maker) through a

Teflon-insulated tungsten electrode
A.M. Systems)

(0.2 mm in diameter,

that was exposed 1.6 mm at the tip. For the

ventromedial thalamic lesions the electrode was lowered and
left in place for 20 s, with current applied at the
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(

following coordinates: +3.5 mm anteroposterior (AP) ,
mm mediolateral

(ML), -4.0 mm dorsoventral

(DV).

±0.5

In order

to create a complete lesion of the•superior colliculus two

electrode placements were necessary.
I

For the superior

colliculus, the electrode was left,in place for 55 s while

current was being applied.

The coordinates for the

superior colliculus lesions were: 40.4 mm AP,

+1.5 mm ML,

7.0 mm DV; and -0.6 mm AP,

Lesions of

+1.5 ML,

-7.0 DV.

-

the nucleus accumbens required only one electrode placement
I
at -6.2 mm AP, +2.2 mm ML, -6.8 mm, DV.
For the nucleus
I

accumbens lesion, current was applied for 30 s.

In all

cases, coordinates were obtained ftom the developing rat

brain atlas of Sherwood and Timira's (1970) .
An equal
I
number of rats from each litter were given bilateral shamlesions using procedures identical to those described

above, except that no current was 'applied.

After surgery,

rats were allowed to recover in a temperature controlled

(30°C)

chamber.

After becoming fully responsive, rats were

placed back with the dam and tested 48 hr and 72 hr later.

Histology
Immediately after behavioral assessment, rats were
I
given an overdose of Nembutal and.perfused intracardially
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with saline followed by a 4% paraformaldehyde solution.

After a 7-day postfixation period, coronal sections were

taken from each brain using a Vibratome 1000 sectioning
apparatus

(Ted Pella, Redding, CA).

Sections were stained

with thionin, coverslipped, and underwent lesion site
verification using a microscope.

Rats that had partial or

inadequate lesions were removed and replaced.

Statistical Analyses

Analysis of Variance

(ANOVA)

for repeated measures

(5

min time blocks) was used for statistical analysis of

distance traveled data.

The first three time blocks,
I
consisting of baseline locomotor assessment, were analyzed
separately from the last nine timej blocks.

Baseline

locomotor activity was not different between sham and
lesioned rats in any of the expieriments.

were analyzed using a 3 x 2
ANOVA.

(day x[ lesion)

Body weight data

repeated measures

To control for litter effects, one rat from each

litter was placed into a particular group.

Litter was then

used as the unit of analysis for the statistical analyses.
With this statistical model each litter, rather than each

rat, was treated as an independent observation (Zorrilla,

1997).

Sex differences were assessed using separate
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No,.’sex differences were found, and

between-spbject ANOVAs.

t.

I

thus the data was presented collapsed’ acrossed male and
!

female rats.

•

■

-

:

;

Post hoc analyses ofjsimple main effects and
1

I

interactions were made using TukeyiHSD tests ' (p < 0.05) .
I
!
For the first and second experiment, in addition to
comparing group differences, the correlation between
!

i

percent ofc brain area lesioned and 1U50,,488-induced
j

I

locomotor; activity was determined using the Pearson
t
I
;
product-moment correlation (r).
For these correlations,
i

!

j
(
rats that| had improper lesions were included in the
I
i
’
analyses.] It was predicted that there would be a negative
correlation between lesion size and U50,488-induced

locomotor! activity, with decreased,locomotor activity being
;

.!

■

'

exhibited! by U50,488-treated rats as the percentage of
!
;

i

brain area lesioned increased.
!

40

I

'

CHAPTER SIX
EXPERIMENT ONE

Overview,

The first experiment was conducted to determine

whether U50,488-induced locomotor activity was attenuated
by lesions of the ventromedial thalamus.

A second purpose

of Experiment 1 was to determine whether lesions of the

ventromedial thalamus produced a general decrease in
I
motoric functioning.
Consequently,1 rats were also injected
i
with the dopamine receptor agonist NPA.

NPA increases

locomotor activity in rats by stimulating dopamine
receptors in the nucleus accumbens and striatum

(Kafetzopoulos,

1986; Kelly & Roberts,

1983), and not by

altering the functioning of nigral output pathways

projecting to the ventromedial thalamus.

Therefore,

it was

predicted that bilateral lesions of the ventromedial
thalamus would attenuate U50,488's locomotor activating
effects, but have no effect on NPA-'induced locomotor

activity.

Method
A total of 28 rats (n = 7 per group)

received

bilateral electrolytic lesions or sham lesions of the
41

ventromedial thalamus on PD 16.

On PD 18, these rats were

singly placed in the testing chambers and baseline
I

locomotor activity was assessed for 15 min.

Sham- and

ventromedial thalamus-lesioned rats were then injected with

saline or U50,488

(5.0 mg/kg, ip) and returned to the

testing chambers for an additional 45 min.

This dose of

U50,488 was chosen because previous studies have shown that

5.0 mg/kg U50,488 reliably produces robust locomotor
activity in preweanling rats

(Collins et al.,

1998; 2000).

Following behavioral testing,1 rats were returned to

their home cage and placed back with the dam.

After an

additional 24 hr, rats were retested as described above,
except that half of the rats (counterbalanced for previous
drug treatment) were given a single injection of saline and

the other half an injection of NPA (0.01 mg/kg,

ip).

This

dose of NPA was chosen because it has been shown that 0.01

mg/kg NPA produces robust locomotor activity in preweanling
I

rats

(Duke et al., 1997).

Results'
Histology

A representative lesion of the ventromedial thalamus
is shown in Figure 4.

Rats that did not have at least 75%
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I

I

Figure 4.
Image of a thionin-stained section indicating
the damage produced by an electrolytic lesion of the
ventromedial thalamus on postnatal1 day 16.

j
of the ventromedial thalamus destroyed on each hemisphere

were removed from the experiment and replaced.
I
I
Body Weight
The.body weights of sham- and ventromedial thalamusj

lesioned rats are shown in Figure 5

(left panel).

Rats in

!
Experiment 1 showed an increase in body weight across the

I
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E

I

Experiment 1

Experiments

Experiments

Figure 5.
Mean body weight (+SEM) i of rats (n = 7-9) from
Experiments 1, 2, and 3.
Regardless of experiment, no body
weight differences were found betwfeen sham or lesioned rats
(£ > 0.05).
1
i
I
i

four days of the experiment
1

[day main effect, F(2, 52)

=

I

50.49, p< 0.001}.

Importantly, body weights of the sham
I

and ventromedial thalamus-lesioned' rats did not differ.
i

1
i

■

Locomotor Activity
I

I

Distance traveled (i.e., locomotor activity) data for
!

;

sham- and ventromedial thalamus-lesioned rats given
systemic injections of U50,488 and NPA are presented in
i

44

Figure 6.

Overall,

18-day-old rats injected with U50,488

(5 mg/kg, ip) exhibited more locomotor activity than
saline-treated rats

[agonist main effect, F(l,

6)

p < 0.001; agonist x time interaction, F(8, 48)
0.001].

= 139.79,

= 19.86, p <

Bilateral lesions of the ventromedial thalamus

attenuated the locomotor activity of 18-day-old rats

injected with U50,488

[lesion x agonist interaction,

F(l, 6)

= 41.53, p < 0.001; lesion x agonist x time interaction,
F(8, 48)

= 2.79, p < 0.05].

Specifically, sham-lesioned

I
rats given U50,488 exhibited more locomotor activity on

time blocks 5-12 than ventromedial thalamus-lesioned rats
given U50,488

(see upper graph, Figure 6).

Bilateral

lesions of the ventromedial thalamus did not completely
I
block U50,488- induced locomotor activity, however, since
ventromedial thalamus-lesioned rats exhibited significantly

more locomotor activity on time blocks 7-12 compared to
saline-treated rats.

Thus, lesions to the ventromedial

i
thalamus result in a disruption of U50,488-induced
locomotor activity.

The extent of' damage to the

ventromedial thalamus was negatively correlated with the

amount of locomotor activity exhibited after systemic

injections of U50,488

(data not shown)

45

[r(14)

= —0.37], but

Ventromedial Thalamus

Figure 6.
Mean distance traveled (+SEM) of rats that had
received sham or electrolytic lesions of the ventromedial
thalamus on postnatal day (PD) 16.
On PD 18, rats (n = 7)
were injected with saline or U50,488 (5 mg/kg, ip) 15 min
into the behavioral testing session (indicated by the
dashed line).
On PD 19 the same fats were injected with
saline or NPA (0.01 mg/kg, ip) 15 min into the behavioral
testing session (indicated by the dashed line).
(a)
Significantly different from the Sham-Saline group (open
symbols).
(b) Significantly different from the Lesion1150,488 group (filled square).

I
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this effect did not reach statistical significance

(p >

0.05).
On the following day (i.e., PD 19), the same rats were

injected with saline or 0.01 mg/kg NPA (see lower graph,
Figure 6).

Rats given systemic injections of NPA exhibited

greater locomotor activity on time blocks 5-10 compared to
rats injected with saline

[agonist1 main effect, F(l,

37.88, p < 0.001; agonist x time interaction, F(8, 48)
28.98, p < 0.001].

=

6)
=

Importantly, lesions of the

ventromedial thalamus failed to affect NPA-induced

locomotor activity, because sham- and ventromedial

thalamus-lesioned rats responded similarly to a systemic
injection of NPA.

I
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CHAPTER SEVEN
EXPERIMENT TWO

Overview
In the second experiment, the'ability of superior

colliculus lesions to attenuate U50,488-induced locomotor
activity was assessed.

As in Experiment 1, rats were

retested with NPA to determine whether superior colliculus

lesions cause a general decrease in motor functioning.

It

was predicted that bilateral lesions of the superior

colliculus would attenuate U50,488's locomotor activating
effects, while having no effect on NPA-induced locomotion.

Method ,

A total of 28 rats

(n = 7 per1group)

received

bilateral electrolytic lesions or sham lesions of the

superior colliculus on PD 16.

On PD 18, these rats were

singly placed in the testing chambers and baseline
locomotor activity was assessed for 15 min.
I

Sham- and

superior colliculus-lesioned rats were then injected with

saline or U50,488

(5.0 mg/kg,

ip)

and returned to the

testing chambers for an additional 45 min.
Following behavioral testing, rats were returned to

their home cage and placed back with the dam.
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After an

additional 24 hr, rats were retested as described above,
except that half of the rats (counterbalanced for previous
drug treatment) were given a single injection of saline and
the other half an injection of NPA (0.01 mg/kg,

ip).

Results
Histology
A representative lesion of the superior colliculus is

shown in Figure 7.

Rats that did not have at least 75% of
i
the superior colliculus destroyed on each hemisphere were

removed from the experiment and replaced.
I
Body Weight
!
The body weights of sham- and superior colliculus-

lesioned rats are shown in Figure 5

(middle panel).

An

increase in body weight was evident in both sham- and

superior colliculus-lesioned rats, with no differences

being apparent between the two treatment groups
effect, F(2,

52)

[day main

= 123.30, p < 0.001] .

Locomotor Activity

Distance traveled (i.e., locomotor activity)

data for

sham- and superior colliculus-lesioned rats given systemic

injections of U50,488 and NPA are presented in Figure 8.
Systemic injections of 5.0 mg/kg U50,488 were again found
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Figure 7.
Image of a thionin-stained section indicating
the damage produced by an electrolytic lesion of the
superior colliculus on postnatal day 16.

to increase the locomotor activity of 18-day-old rats

[agonist main effect, F(l, 6)

time interaction, F(8, 48)

= 29.50, p < 0.001; agonist x

= 8.75, p < 0.001].

The

U50,488-induced locomotor activity exhibited by these rats

was diminished by bilateral lesions of the superior

colliculus

[lesion x agonist x time interaction, F(8, 48)

2.79, p < 0.05] .

More precisely, sham-lesioned rats given

50

=

Figure 81
Mean distance traveled 1 (+SEM) of rats that had
received sham or electrolytic lesions of the superior
colliculus on postnatal day (PD) 16.
On PD 18, rats (n =
7) were injected with saline or U50,488 (5 mg/kg, ip) 15
min into the behavioral testing session (indicated by the
dashed line).
On PD 19 the same fats were injected with
saline or NPA (0.01 mg/kg, ip) 15 !min into the behavioral
testing session (indicated by the ’dashed line) .
(a)
Significantly different from the Sham-Saline group (open
symbols).
(b) Significantly different from the LesionU50,488 group (filled square).
;
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i

I

U50,488 had greater locomotor activity on time blocks 5-10

when compared to superior colliculus-lesioned rats given
U50,488

(see upper graph, Figure 8).

Lesioning the

superior colliculus was not sufficient to block the
locomotor activity induced by systemic injections of
I
U50,488, since the Lesion-U50,488 group was significantly
more active than saline controls

Therefore,

(see Figure 8).

superior colliculus lesions, like lesions of the

ventromedial thalamus, attenuated the locomotor activity

produced by systemic injections of U50,488.
In order to examine whether non-specific or incomplete

brain lesions affect the locomotor activity produced by

K-opioid receptor agonist, a correlational analysis examined
the relationship between lesion size and U50,488-induced
locomotor activity.

A scatterplot1 representing the

relationship between lesion size and the distance traveled
scores of all lesioned-rats given systemic injections of
U50-488 is shown on Figure 9.

As predicted, the amount of

locomotor activity exhibited by rats treated with U50,488
was negatively correlated with the amount of damage to the

superior colliculus

(see Figure 9>

[r(14)

= -0.37].

Thus,

it is not likely that the reduction in locomotor activity
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Superior Colliculus

Figure 9.
Scatterplot representing the relationship
between lesion size and distance traveled scores of U50488-treated rats.
Distance traveled scores were summated
over the last 45 min of the testing session (i.e., the
period beginning immediately after U50,488 was injected).

observed in superior colliculus-lesioned rats is a result
of non-specific lesions to surrouniding brain areas.

I•
When the same rats were retested with saline or NPA
.
1
(0.01 mg/kg, ip) on PD 19, both sham- and superior

colliculus-lesioned rats exhibited1 greater locomotor
activity on time blocks 5-10 when given NPA [agonist x time

interaction, F(8, 24)

= 7.18, p < 0.001].

Lesioning the

superior colliculus did not disrupt NPA-induced locomotor
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activity, because no differences between the Sham-NPA group
and the Lesion-NPA group were observed.

I

I
I
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CHAPTER EIGHT
EXPERIMENT THREE

Overview,
I
The first two experiments were conducted to determine
I
whether disruptions of the nigrothalamic and nigrotectal
i
i
pathways attenuate U50,488- and NPA-induced locomotor

activity.

The purpose of the third experiment was to

determine whether lesioning another brain region causes
non-specific reductions in U50,488Linduced locomotion.

Simply stated, Experiment 3 was conducted to provide an
anatomical control in which lesions to a particular brain
I
region were not expected to affect1 U5'0,488-induced

locomotor activity.

To this end, rats were given sham or
i

bilateral lesions of the nucleus accumbens and tested with
U50,488 and NPA on two consecutive days.
It was expected
I
that lesions to the nucleus accumbens would not affect

U50,488-induced locomotor activity.

However, because NPA-

induced locomotor activity is mediated via dopaminergic
mechanisms in the striatum and nucleus accumbens
(Kafetzopoulos,

1986; Kelly & Roberts,

1983),

it was

hypothesized that lesions to the nucleus accumbens would
attenuate NPA-induced locomotor activity.
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Method

A total of 36 rats

(n = 9 per group) received

bilateral electrolytic lesions or sham lesions of the

nucleus accumbens on PD 16.

On PD, 18, these rats were

singly placed in the testing chambers and baseline
locomotor activity was assessed for 15 min.

Sham- and

nucleus accumbens-lesioned rats were then injected with

saline or U50,488

(5.0 mg/kg,

ip) and returned to the

testing chambers for an additional 45 min.
Following behavioral testing, rats were returned to

their home cage and placed back with the dam.

After an

additional 24 hr, rats were retested as described above,
except that half of the rats (counterbalanced for previous

drug treatment) were given a single injection of saline and

I
the other half an injection of NPA (0.01 mg/kg, ip).

Results

Histology

J
I

,

A representative lesion of the nucleus accumbens is

I
shown in Figure 10.

Rats that did not have at least 50% of

the nucleus accumbens destroyed on each hemisphere were
removed from the experiment and replaced.
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i
i

I

i
i

Figure 10.
Image of a thionin-stained section indicating
the representative damaged produced by an electrolytic
lesion of the nucleus accumbens on'postnatal day 16.
I

1
I
'

I

Body Weight

!
I

The body weights of sham- and!nucleus accumbens1

I

lesioned rats are shown in Figure 5

(right panel).

All

I

rats showed a significant increase 1 in body weight across
i

'
’
the four days of the experiment

,
[day main effect, F(2, 52)

I

= 142.42,'p < 0.001].

f

In particular, sham- and nucleus

I
i

i

:

j
.
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i

accumbens-lesioned rats exhibited similar body weight gain
during the experiment.
Locomotor Activity

Distance traveled (i.e, locomotor activity)

data for

sham- and nucleus accumbens-lesioned rats given systemic
injections of U50,488 and NPA are presented in Figure 11.
Systemically administered U50,488 significantly enhanced

the locomotor activity of 18-day-old rats compared to

saline controls

[agonist main effect, F(l, 8)
I

0.001; agonist x time interaction, F(8,
0.001].

64)

= 103.37, p <

= 6.35, p <

Contrary to my predictions, bilateral lesions to

the nucleus accumbens disrupted the U50,488-induced

locomotor activity of 18-day-old rats [lesion x agonist
I
interaction, F(l, 8) = 7.31, p < 0^05; lesion x agonist x

= 2.31, (p < 0.05] .
I
Specifically, the Sham-U50,488 group exhibited greater
time interaction, F(8,

64)

activity on time blocks 6 and 8-12ithan rats in the LesionI
U50,488 group (see upper graph, Figure 11).
Lesioning the

nucleus accumbens, however, did not completely prevent

U50,488 from enhancing the locomotor activity of 18-day-old
rats, since the Lesion-U50,488 group was more active during
time blocks 5-12 compared to saline-treated rats
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(see

I
I

Figure ll'.
Mean distance traveled !(±SEM) of rats that had
received sham or electrolytic lesions of the nucleus
accumbens'on postnatal day (PD) 16.1 On PD 18, rats (n = 7)
were injected with saline or U50,48'8 (5 mg/kg, ip) 15 min
into the behavioral testing session' (indicated by the
dashed line) .
On PD 19 the same ra'ts were injected with

saline oriNPA (0.01 mg/kg, ip) 15 min into the behavioral
testing session (indicated by the dashed line).
(a)
Significantly different from the Sham-Saline group (open
symbols). : (b) Significantly different from the LesionU50,488 group (filled square).
j
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Figure 11) .

Thus, like lesions of' the nucleus accumbens,

lesions of the ventromedial thalamus and superior

colliculus attenuated the U50,488-induced locomotor
activity of 18-day-old rats.
On PD 19, these same rats were injected with saline or

NPA (0.01 mg/kg, ip).

Systemic injections of NPA produced

robust locomotor activity in both sham- and nucleus
accumbens-lesioned rats, with these differences reaching
statistical significance on time blocks 5-9

effect, F(l,

8)

[agonist main

= 112.36, p < 0.00.1; agonist x time

interaction, F(8, 64)

= 24.08, p <i 0.001].
i

Unexpectedly,

lesions of the nucleus accumbens did not affect the NPAinduced locomotor activity of 19-day-old rats.

This result

I
was surprising since the nucleus accumbens has substantial

numbers of dopamine receptors

(Gelbard, Teicher,

Baldessarini, 1989; Rao, Molinoff,' & Joyce, 1991)

Faedda, &
and NPA's

effects are known to be mediated by dopamine receptors.

i
i

I
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CHAPTER NINE
DISCUSION,
I

Rationale'
1
The purpose of the present study was to determine the

neuronal circuitry responsible for■K-opioid-mediated

locomotion in preweanling rats.

Convincing evidence now

exists that systemic injections of U50,488 produces its
locomotor stimulating effects by activating K-opioid
receptors in the substantia nigra pars reticulata (Collins

et al., 2000).

It is uncertain which nigral output pathway

is responsible for mediating the U50,488-induced locomotor
activity of preweanling rats, but it is possible that Kopioid receptor stimulation enhances locomotion by

inhibiting GABAergic projections from the substantia nigra
pars reticulata to the ventromedial thalamus and superior
colliculus.

I

Nonontogenetic studies have provided the only evidence
that the nigrostriatal and nigrotectal pathways may be
important for K-opioid-mediated locomotion.

Specifically,

although systemic administration of U50,488 does not

produce locomotor activity in adult rats

1988; Leyton & Stewart,

(Jackson &' Cooper,

1992), unilateral microinjections
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of U50,488 into the substantia nigra pars reticulata

produces robust contralateral circling (Matsumoto et al.,

1988a).

i
Importantly, lesions of the ventromedial thalamus

or superior colliculus attenuate U50,488-induced circling
in adult rats

present study,

(Thompson & Walker,

i992).

Therefore, in the

16-day-old rats were given bilateral lesions

of the ventromedial thalamus

colliculus (Experiment 2)

(Experiment 1)

or superior

followed, two days later (i.e.,

on PD 18) ', by a systemic injection, of U50,488.

It was

I
predicted that bilateral lesions of the ventromedial
thalamus or superior colliculus would attenuate the

U50,488-induced locomotor activity of preweanling rats.

Role of the Ventromedial Thalamus and
Superior Colliculus in U50,488and NPA-induced Locomotion

Systemic administration of U50,488 produced robust
I
locomotor activity in 18-day-old rats (see Figures 6, 8,
and 11).

That U50,488 caused this behavioral effect was

not surprising, because systemic administration of U50,488
reliably increases the locomotor activity of preweanling

1996; Collins et al.,

rats

(Bolanos et al.,

al. ,

1997; Jackson & Kitchen,

McLaughlin et al., 1995) .

1998; Duke et

1989; McDougall et al.,

As expected, lesions to the
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1997;

ventromedial thalamus or superior colliculus significantly
;
i
decreased the U50,488-induced locomotor activity of 18-dayi

old rats.; More specifically, rats[with bilateral lesions
[
'
'
I
‘
'
of the ventromedial thalamus or superior colliculus
!
i
!
■
.
exhibited an attenuated response to a systemic injection of
i
(see upper graphs, Figures[6 and 8).
Importantly,
i
'
;
the same lesions did not disrupt the locomotor activity

U50,488

produced by systemic injections of,the dopamine agonist NPA
i■ .
‘
,
i
(see lower graphs, Figures 6 and 8).
Regardless of the

brain area lesioned (ventromedial thalamus or superior
i
I
■
' '■ ■
colliculus), systemic injectipns of NPA stimulated the
locomotor activity of sham and lesioned rats in a similar
manner.

When, considered, together, it is apparent that the
,

I

nigrothalamic and nigrotectal,pathways are part of an

integral bircuitry responsible.forithe ability of K-opioidi

-

:

.

’

. ,

mediated locomotor activity of preweanling rat's.
i ■
'
/ '
the functioning of non-opioid motor systems

Moreover,

(i.e., those

systems mediating NPA-induced locomotion) were not affected
|

.

1

‘

by lesions of the ventromedial thalamus and superior
1

i
I

colliculus.

This effect is important because.it reveals

I

that ventromedial thalamus and superior colliculus lesions
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specifically disrupt the stimulatory actions of K-opioid
I

receptor agonists.

Lesions of the ventromedial thalamus or superior

colliculus alone were not capable of completely blocking
U50,488-induced locomotor activity: (see Figures 6 and 8).
i

Several explanations may account for this effect.

First,

I
it is possible that lesions of the', ventromedial thalamus
and superior colliculus were incomplete, thus allowing
U50,488-induced locomotor activity1to be expressed at a

reduced level.

I
This explanation seems unlikely, however,

since care was taken to ensure that only animals with

complete lesions were included in the experiments.
Second,
I
it is possible that both the ventromedial thalamus and
I
superior colliculus are necessary for the full expression
of K-opioid-mediated locomotor activity.

In other words,

when only one brain area was destroyed, the remaining non-

lesioned brain area (i.e., the ventromedial thalamus or
i
superior colliculus) may have been sufficient to produce a
I
weakened, although significant, level of U50,488-induced

locomotor activity.

Third, the inability of ventromedial

thalamus and superior colliculus lesions to completely
attenuate U50,488-induced locomotor activity, leaves open
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the possibility that other nigral output pathways

(e.g.,

pathways projection to the striatum and pedunculopontine
nucleus) may mediate some of the behavioral effects induced
by K-opioid receptor agonists.
eliminated by the present study.

This possibility cannot be
In any event,

it remains

certain that the nigrotectal and nigrothalamic pathways

mediate, at least partially, the locomotor activity
produced by K-opioid receptor agonists.

Role of the Nucleus Accumbens in
U50,488-Induced Locomotion

For this study, it was important to determine the
specificity of lesion-induced effects.

Thus, an additional

experiment was conducted to determine whether lesioning an

unrelated brain structure would reduce U50,488-induced
locomotion.

The nucleus accumbens was the brain region

chosen as the anatomical control for two reasons. First,
lesioning the nucleus accumbens was not expected to affect
U50,488-induced locomotor activity, since U50,488's

locomotor activating effects are known to be mediated by

the substantia nigra pars reticulata (Collins et al.,

2000) .

Second, lesioning the nucleus accumbens was

expected to disrupt NPA-induced locomotor activity,
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since

NPA's actions are known to be mediated by the mesolimbic

pathway (Kafetzopoulos,

1986; Kelly & Roberts,

1983) .

The

results from Experiment 3, however, suggest that I did not

choose an appropriate anatomical control.

Perhaps the most surprising finding was that the
nucleus accumbens lesions attenuated the U50,488-induced

locomotor activity of preweanling rats.

More precisely,

rats with lesions to the nucleus accumbens exhibited a

decreased responsiveness to a systemic injection of U50,488

(see upper graph, Figure 11).

These findings are

problematic because they complicate interpretation of data
from the other lesion experiments.,

Put another way,

because lesions of the nucleus accumbens, like lesions of
I
the ventromedial thalamus and superior colliculus,
attenuated U50,488-induced locomotor activity,

it remains

possible that lesioning any brain region may reduce the

locomotor activity produced by K-opioid receptor
stimulation.

Even so, this explanation,

that U50,488-induced

locomotor activity is attenuated by non-specific brain
lesions,,is unlikely for two reasons.

First, there was a

strong correlation between U50,488-induced locomotor
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activity and the amount of damage produced by superior
colliculus lesions

(see Experiments 2 and Figure 9).

Moreover, lesions to the ventromedial thalamus and superior

colliculus did not produce a global decrease in motor
ability nor did they decrease NPA-induced activity.

When

considered together, these findings provide strong evidence

that the ventromedial thalamus and' superior colliculus
mediate the stimulatory effects of K-opioid receptor
agonists and do not cause a general disruption of motor

functioning.

Second, there is evidence to .suggests that lesions of
the nucleus accumbens may indirectly affect the locomotor
stimulating effects of U50,488 by way of direct projections
to the substantia nigra pars reticulata.

More precisely,

recent anatomical studies have demonstrated that the
nucleus accumbens provides input to cell bodies in

substantia nigra pars reticulata (Deniau, Menetrey,

&

Thierry, 1994; Montaron, Deniau, Menetrey, Glowinski,
Thierry,

1996).

&

This is important, because nucleus

accumbens lesions may have indirectly affected U50,488induced locomotor activity by altering the function of the
nigrothalamic and nigrotectal pathways.
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Behavioral

I

evidence for this explanation is available, since the
U50,488-induced locomotor activity-of preweanling rats is
decreased by dopamine receptor antagonist drugs

al.,

1997; Nazarian, Rodarte-Freeman,

(Duke et

& McDougall,

When these results are considered ^together,

1999).

it appears that

the nucleus accumbens may not have, been an appropriate

anatomical control for the present study, particularly
because the nucleus accumbens may be a component of the
circuitry mediating U50,488-induced locomotor activity.
I
Role of the Nucleus Accumbens in
NPA-induced Locomotion
I

Although lesions of the nucle.us accumbens were
effective in disrupting U50,488-induced activity, the same
lesions did not disrupt the locomo’tor activating effects of
NPA (see lower graph, Figure 11).

This finding was

unexpected because the nucleus acc/umbens has a substantial
number of dopamine receptors that are evident as early as

the first postnatal week (Gelbard et al.,

1991).

Moreover,

1989; Rao et al.,

lesions to the nucleus accumbens have

been shown to disrupt the NPA-induced locomotor activity of
adult rats

(Kafetzopoulos,

1986; Kelly & Roberts,

1983).

Importantly, adult and preweanling rats do not demonstrate

a qualitatively different behavioral profile after systemic
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administration of NPA, as.both age'groups show marked
increases in locomotor activity after NPA treatment
et al.,

1997; McDougall, Crawford, 1 & Nonneman,
i

Mestlin & McDougall, 1993).

Consequently,

(Duke

1992;

it was

reasonable to expect that nucleus accumbens lesions would
I
affect the NPA-induced locomotor activity of preweanling
and adult rats similarly.
At least two explanations may account for the

inability of nucleus accumbens lesions to disrupt NPAinduced activity.

First, it is possible that lesions of

the nucleus accumbens were not complete enough to disrupt

the locomotor enhancing effects of' NPA, since complete
lesions of the nucleus accumbens are necessary to disrupt
the behavior of adult rats

Roberts, 1983).

(Kafetzopoulos,

1986; Kelly &

In the present study, histological results

revealed that many of the rats included in the analyses had

only partial lesions

(«50%) of the nucleus accumbens.

Thus,

the extent of nucleus accumbens damage may have been

insufficient to disrupt the NPA-induced locomotor activity
of preweanling rats.

Second,

it is possible that surviving regions of the

nucleus accumbens or striatum may have compensated for the
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loss of dopaminergic activity.

Consistent with this

hypothesis are studies showing that neurochemical and

behavioral deficits are only evident when more than 95% of
,
I

dopamine cell bodies are destroyed (for a review,
Robinson, Castaneda, & Whishaw,

1990).

see

Moreover,

extracellular concentrations of dopamine remain unaffected
(i.e., are within normal control levels) even when 80% of

dopamine neurons in the substantia nigra are lesioned
(Castaneda, Whishaw, & Robinson, 1,990) .

These findings may

be the result of compensatory changes by the remaining
I

population of dopamine neurons,

including, but not limited
I

to, increased dopamine synthesis and release.

Similar

compensatory changes in dopaminergic activity may account
for the lack of behavioral deficits exhibited by 6-

hydroxydopamine-treated rats given systemic injections of a

dopamine agonist.

For instance, amphetamine-induced

locomotion and rearing are not disrupted until dopamine
depletion reaches 95%

al., 1990).

(Castaneda et al.,

In light of these findings,

1990; Robinson et
it is plausible

that compensatory changes in dopaminergic activity may have

allowed for the expression of NPA-induced locomotor
activity!in preweanling rats.
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I

.

'Conclusion

i
!
The present study has demonstrated that the locomotor
i
i
activity produced by systemic administration of U50,488 is,
at least partially, mediated by the ventromedial thalamus

and superior colliculus.
This conclusion is supported by
!
'
I
>
I
results showing that: (a) lesions to the ventromedial
I ' '
1
thalamus land superior colliculus attenuate U50,488-induced
■
1
locomotor activity, and (b) the same lesions fail to
'!
I '
disrupt the locomotor activity produced by systemic
I
1
'
.
i
1
injections of NPA.
The specificity of these lesion-induced
effects i's somewhat ambiguous, because nucleus accumbens
I
1
i
•
1
lesions also attenuated the locomotor activity of U50,488'
‘
i*
-J
treated rjats.
The latter finding is difficult to

!
:
;
interpret!, since the nucleus accumbens may indirectly
■
i
affect th!e activity of the ventromedial thalamus. At
I

-

present, therefore, the most parsimonious conclusion is
that the ventromedial thalamus and.superior
colliculus are
T
!
the primary output structures mediating the U50,488-induced

i
locomotor activity of preweanling rats.
l

Future research

will be heeded to determine whether the mesolimbic dopamine

pathway i s also important for K-opioid-mediated locomotion.
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